Acurx Shares Surge 37% After Reverse Split as $9M Equity Raise Looms

Introduction

Acurx Pharmaceuticals Inc (NASDAQ: ACXP) is a clinical‐stage biopharmaceutical company headquartered in Staten Island, New York, focused on developing a new class of small-molecule antibiotics. Its lead candidate, ibezapolstat, targets DNA polymerase IIIC to treat Clostridioides difficile infections. The company’s strategy also addresses other Gram-positive priority pathogens identified by the World Health Organization, the Centers for Disease Control and Prevention, and the U.S. Food and Drug Administration.

Corporate Structure

Founded in 2018, Acurx employs between 11 and 50 professionals across research, development, regulatory affairs, and corporate functions. The management team includes David P. Luci, President and Chief Executive Officer; Robert J. DeLuccia, Executive Chairman; and Robert G. Shawah, Chief Financial Officer. Collectively, the leadership possesses extensive experience in antibiotic drug development, corporate finance, and biopharmaceutical operations.

Antibiotics by freestocks

Recent Developments and News

On August 4, 2025, the board and shareholders approved a 1-for-20 reverse stock split to meet Nasdaq’s minimum bid price requirement. Post-split trading began on August 5, 2025, under the existing ticker symbol ACXP.
In filings dated November 10–14, 2025, Acurx submitted a prospectus (Rule 424B3) outlining up to 585,000 additional shares for resale under its Lincoln Park Capital Fund agreement, potentially raising up to $9.0 million, and amended a Schedule 13G/A indicating that two investors each hold 4.99% of outstanding shares. The Form 10-Q for the quarter ended September 30, 2025, was filed on November 12, 2025.

On December 8, 2025, ACXP closed at $4.40 per share, reflecting a 37.07% increase from the prior close of $3.21. Trading volume reached 124,055 shares, within a 52-week range of $3.17 (December 3, 2025) to $25.00 (January 6, 2025).

Financial and Strategic Analysis

As of October 17, 2025, Acurx’s market capitalization was approximately $9.2 million, based on 2.09 million shares outstanding. Key trailing-twelve-month metrics include:

• EPS: –8.54
• P/E (TTM): –0.51
• Forward P/E (NTM): 1.11
• EBITDA: –$7.2 million
• ROE: 227.8%

The reverse split addresses listing compliance but reduces free float. The Lincoln Park Capital Fund facility provides up to $12.0 million in aggregate proceeds (including $3.0 million already received), contingent on market conditions. The reliance on such equity financings and a narrow market cap present execution risk until commercial revenues begin.

Market Position and Industry Context

Acurx operates within an antibiotic sector characterized by increasing antimicrobial resistance and limited new therapies. Its GPSS® platform aims to inhibit Gram-positive bacterial DNA replication, with pipeline candidates targeting MRSA, VRE, drug-resistant Streptococcus pneumoniae, and anthrax. The competitive landscape includes established pharmaceutical firms and emerging biotech companies pursuing novel mechanisms. Regulatory pathways for antibiotics typically require extensive clinical data and post-approval stewardship commitments, impacting development timelines and commercial strategies.

tl;dr

• On August 4, 2025, Acurx executed a 1-for-20 reverse stock split for Nasdaq compliance.
• The company filed a prospectus on November 10 and Form 10-Q on November 12, 2025, detailing a potential $9.0 million equity raise and quarterly financial results.
• Schedule 13G/A filings on November 14, 2025, show two investors each holding 4.99%.
• ACXP shares increased by 37.07% to $4.40 on December 8, 2025, amid 124,055 shares traded.
• Ibezapolstat is Phase 3 ready, with plans to initiate international trials in 2026, subject to securing additional financing.